IP Library Granted Patent US 10,806,568
Granted Patent B2
US 10,806,568 · App. 16/199,670 · Granted Oct 20, 2020

Implantable scaffolds for treatment of sinusitus

Inventors: Changcheng You (Northbridge, MA); Quynh Pham (Methuen, MA); Danny Concagh (Medfield, MA)
Assignee: LYRA THERAPEUTICS, INC.
A61F2/18A61F2/90A61K31/58A61L27/18A61L27/26A61L27/34A61L27/54A61L27/56A61L31/06A61L31/10A61F2/186A61F2210/0004A61F2250/0031A61F2250/0067A61L2300/222A61L2300/41A61L2300/604A61L2300/608
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,568
App. No.
16/199,670
Granted
Oct 20, 2020
Kind
B2
Abstract

This disclosure describes various sinus scaffolds having fiber-based and non-fiber based designs, materials, devices, kits and methods that may be used to treat chronic sinusitis. These designs vary in form, dimension, and delivery location (i.e. maxillary, frontal, ethmoidal, sphenoidal sinuses, and middle meatus). In addition therapeutic agent(s) may optionally be included within the scaffolds for local delivery over a brief or extended period of time.

Claims (25)

1. A method of treatment of a human patient with rhinosinusitis, comprising:

a) providing a scaffold comprising

i) a layer comprising mometasone furoate and a biodegradable polymer material and

ii) a therapeutic-agent-free polymer topcoat layer, said topcoat layer positioned on said layer so as to control the release of the mometasone furoate; and

b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient with chronic rhinosinusitis.

2. The method of claim 1 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.

3. The method of claim 1 , wherein said patient has failed medical management based on the administration of oral steroids.

4. The method of claim 1 , wherein said patient has failed medical management based on the administration of topical steroids.

5. A method of treatment of a subject with a sinus condition, comprising:

a) providing a scaffold comprising

i) a layer comprising mometasone furoate and a polymer material and

ii) a polymer topcoat layer, said topcoat layer positioned on said layer so as to control the release of the mometasone furoate; and

b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a subject with a sinus condition.

6. The method of claim 5 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.

7. The method of claim 5 , wherein said subject is a human patient that has failed medical management based on the administration of oral steroids.

8. The method of claim 5 , wherein said subject is a human patient that has failed medical management based on the administration of topical steroids.

9. A method of treatment of a subject with a sinus condition, comprising:

a) providing a scaffold comprising a layer comprising mometasone furoate and a polymer material; and

b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of said subject.

10. The method of claim 9 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.

11. The method of claim 9 , wherein said subject is a human patient that has failed medical management based on the administration of oral steroids.

12. The method of claim 9 , wherein said subject is a human patient that has failed medical management based on the administration of topical steroids.

13. A method of treatment of a subject with a sinus condition, comprising:

a) providing i) a scaffold comprising a layer comprising mometasone furoate and a polymer material and ii) a human subject that has previously failed medical management based on the administration of oral or topical steroids; and

b) delivering said scaffold to the middle meatus of said subject under conditions where the scaffold delivers said mometasone furoate from the middle meatus to a sinus cavity of said subject.

Assignments (2)
CHANGE OF NAME Recorded Jan 17, 2020
From: 480 BIOMEDICAL, INC.
To: LYRA THERAPEUTICS, INC.
Reel/Frame 051637/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2019
From: YOU, CHANGCHENG; PHAM, QUYNH; CONCAGH, DANNY
To: 480 BIOMEDICAL, INC.
Reel/Frame 047969/0117 →
Continuity (5)
Continuation 15197686 · Jun 29, 2016
Provisional Application 62332134 · May 5, 2016
Provisional Application 62289982 · Feb 2, 2016
Provisional Application 62186030 · Jun 29, 2015
Related Publication 20190117383A1 · Apr 25, 2019